Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · IEX Real-Time Price · USD
3.820
-0.050 (-1.29%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Aldeyra Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ALDX stock have an average target of 9.33, with a low estimate of 8.00 and a high estimate of 10. The average target predicts an increase of 144.24% from the current stock price of 3.82.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 6, 2024.
Analyst Ratings
The average analyst rating for ALDX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +161.78% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $10 | Buy | Reiterates | $10 | +161.78% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $10 | Hold → Buy | Upgrades | $10 | +161.78% | Apr 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +161.78% | Apr 2, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $25 → $8 | Strong Buy | Maintains | $25 → $8 | +109.42% | Oct 17, 2023 |
Financial Forecast
Revenue This Year
33.83M
Revenue Next Year
52.74M
from 33.83M
Increased by 55.91%
EPS This Year
-0.18
from -0.64
EPS Next Year
-0.45
from -0.18
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.0M | 105.0M | 135.0M | 154.4M | 243.8M |
| Avg | 33.8M | 52.7M | 76.1M | 116.2M | 177.9M |
| Low | n/a | 18.3M | 50.9M | 84.6M | 133.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 210.4% | 156.0% | 102.7% | 109.9% |
| Avg | - | 55.9% | 44.3% | 52.6% | 53.1% |
| Low | - | -45.8% | -3.6% | 11.1% | 14.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.99 | 0.53 | 1.37 | 1.37 | 2.34 |
| Avg | -0.18 | -0.45 | 0.09 | 0.78 | 1.45 |
| Low | -0.64 | -0.88 | -0.55 | 0.22 | 0.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,410.4% | 202.1% |
| Avg | - | - | - | 757.8% | 87.5% |
| Low | - | - | - | 138.6% | -21.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.